查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018818

泌尿生殖系統藥物市場：2026-2032年全球市場預測（依適應症、治療分類、給藥途徑、劑型、銷售模式、通路和最終用戶分類）

Genitourinary Drugs Market by Indication, Therapeutic Class, Route Of Administration, Formulation, Sales Model, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，泌尿生殖系統藥物市場價值將達到 415.4 億美元，到 2026 年將成長至 433.3 億美元，到 2032 年將達到 558.8 億美元，複合年成長率為 4.32%。

主要市場統計數據
基準年 2025 415.4億美元
預計年份：2026年 433.3億美元
預測年份 2032 558.8億美元
複合年成長率 (%) 4.32%

全面概述了影響泌尿生殖系統治療及其取得的人口統計、臨床、監管和技術因素。

泌尿生殖系統治療領域正經歷著一場由人口結構、臨床和技術因素共同驅動的動態變革。隨著已開發國家人口老化，良性前列腺增生和膀胱過動症疾病的盛行率不斷上升，同時，醫療保健模式轉移的轉變和患者期望的不斷變化，也促使人們對兼具療效和耐受性的藥物提出了更高的要求。同時，藥理學和藥物遞送技術的進步，拓展了口服、注射和外用等多種給藥途徑，為臨床醫生提供了更多個人化治療的手段。

泌尿生殖健康服務提供方式的重新定義，在研發、商業化和供應韌性方面的結構性轉變進行了詳細的考察。

泌尿生殖系統藥物市場正經歷一場變革性的轉變，不僅體現在新產品的分階段上市，也體現在研發、商業化和醫療服務模式的結構性變革。臨床創新正透過聯合治療和新型作用機制拓展治療邊界，而藥物科學則正在開發新的給藥途徑，以提高患者的依從性和耐受性。這些科學進步是由商業性模式的轉變所驅動的，例如以數位化為先導的病人參與模式、線上藥局的興起，以及對真實世界證據的日益重視，以支撐提案的價值主張。

重點分析 2025 年關稅變化將如何影響泌尿生殖系統藥物整個價值鏈的採購、籌資策略和商業運作。

美國將於2025年實施關稅，這為泌尿生殖系統藥物的整個價值鏈帶來了多重挑戰，也促使企業採取相應的因應措施。對活性成分、輔料和特殊包裝材料等生產投入的成本審查日益嚴格，迫使企業重新評估籌資策略。為此，一些製造商加快了供應商多元化進程，並探索區域採購方案以降低關稅波動帶來的風險。另一些製造商則加強了策略性庫存管理和期貨合約，以平衡整個生產週期的採購成本。

關鍵細分洞察揭示了適應症、治療分類、分銷管道和劑型選擇如何影響獲取、處方和商業化策略。

要了解泌尿生殖系統治療領域臨床和商業性機會的交會點，需要敏銳地意識到細分市場中的細微差別。從適應症來看，該領域涵蓋良性前列腺增生、勃起功能障礙、間質性膀胱過動症炎、膀胱過動症和尿道感染，每種疾病都有其獨特的病程、診斷路徑和終點，這些都會影響治療方法的選擇和醫療保險報銷。從治療分類來看，該領域包括5α還原酶抑制劑、α受體阻斷劑、抗膽鹼能藥物、BETA3促效劑、聯合治療和PDE5抑制劑，清楚地界定了既定的標準治療方案和正在積極創新的領域。

關鍵區域洞察突顯了北美、歐洲、中東和非洲以及亞太地區的人口、監管和分銷差異如何影響獲取和採用。

區域趨勢對泌尿生殖系統市場的治療重點、法規環境和分銷模式有顯著影響。在美洲，人口老化、大規模的基層醫療體系和健全的專業醫療網路推動了對慢性病管理策略的持續需求。同時，健保報銷機制和處方藥目錄選擇流程也日益凸顯了清晰的價值證明和療效數據的重要性。相較之下，歐洲、中東和非洲與區域支付方的談判以及公共採購機制導致了不同的市場採納路徑，一些市場傾向於集中競標，而另一些市場則優先考慮與臨床指南保持一致。

對現有企業產品組合、專業創新者和夥伴關係關係如何推動差異化定位和商業化成功進行策略競爭分析。

泌尿生殖領域的競爭格局呈現出多元化的特點，既有成熟的大型製藥企業公司，也有專注於特定適應症和新型製劑的靈活中型企業。大型成熟製藥公司正利用其商業規模以及與醫院和藥房建立的穩固關係，拓展其在5α-還原酶抑制劑和α阻斷劑傳統治療領域的產品組合。同時，專業公司和新參與企業則專注於差異化的作用機制、聯合治療以及改進的給藥系統，以解決耐受性和依從性問題，並力求透過與醫生合作以及產生針對性證據來創造價值。

為製藥業領導者提供一系列切實可行的建議，以協調研發重點、供應鏈韌性和通路策略，從而加速產品推廣。

致力於最大化臨床影響和商業性回報的行業領導者應採取一系列切實可行的優先事項，將創新、可及性和營運韌性相結合。首先，應將研發重點放在已證實存在未滿足需求的適應症上，並投資於能夠提高患者依從性和耐受性的聯合治療和給藥技術，從而加強與支付方和臨床醫生之間的價值對話。其次，應透過以下方式增強供應鏈韌性：實現原料藥(API) 和組件來源多元化；盡可能建立區域生產能力；以及實施健全的可追溯性方案，以降低貿易中斷帶來的風險。

一種透明且可重複的調查方法，結合了與專家的直接互動、二手文獻的整合以及基於情境的運行分析。

本研究採用高度透明且可重複的調查方法，整合一手和二手訊息，強調資訊來源的檢驗檢驗和專家核實。一手資訊包括對臨床醫生、支付方、經銷商以及研發負責人進行的結構化訪談，以及旨在了解處方行為和分銷管道偏好的匿名醫療專業人員問卷。二手資訊則利用同行評審文獻、監管指導文件、臨床試驗註冊數據和企業資訊披露，為臨床概況、安全性考慮和製劑趨勢提供背景信息。

本報告總結瞭如何整合創新、證據產生和供應鏈穩健性以確保患者獲得治療和商業性永續性的結論。

總之，泌尿生殖系統治療市場正處於一個策略性十字路口，臨床創新、不斷發展的通路和營運韌性在此交匯，共同塑造其未來的發展方向。治療分類、聯合治療和製劑技術的進步有望改善患者的治療效果，但要實現這些目標，需要使循證醫學的產生與支付方的期望相符，確保可靠的供應鏈，並構建能夠適應日益數位化和多元化通路環境的商業模式。那些投資於利用真實世界數據並根據區域和通路的特定趨勢調整打入市場策略相關人員，將更有能力將臨床進展轉化為永續的患者用藥途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：泌尿生殖系統藥物市場：依適應症分類

  • 良性攝護腺增生
  • 勃起功能障礙
  • 間質性膀胱炎
  • 膀胱過動症
  • 尿道感染

第9章 泌尿生殖系統藥物市場（依治療類別分類）

  • 5α-還原酶抑制劑
  • α受體阻斷劑
  • 抗膽鹼能藥物
  • BETA3促效劑
  • 聯合治療
  • PDE5抑制劑

第10章：泌尿生殖系統藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第11章：泌尿生殖系統藥物市場（依劑型分類）

  • 膠囊
  • 注射藥物
  • 口服液
  • 藥片

第12章：泌尿生殖系統藥物的市場銷售模式

  • 非處方藥
    • 店面銷售
    • 線上
  • 處方箋

第13章：泌尿生殖系統藥物市場：依通路分類

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第14章：泌尿生殖系統藥物市場：依最終用戶分類

  • 診所
    • 全科診所
    • 泌尿系統診所
  • 居家醫療
  • 醫院
    • 二級醫療機構
    • 專科診所
    • 三級醫療機構

第15章：泌尿生殖系統藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：泌尿生殖系統藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：泌尿生殖系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 美國泌尿生殖系統藥物市場

第19章 中國泌尿生殖系統藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-ED54C46E88A6

The Genitourinary Drugs Market was valued at USD 41.54 billion in 2025 and is projected to grow to USD 43.33 billion in 2026, with a CAGR of 4.32%, reaching USD 55.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 41.54 billion
Estimated Year [2026] USD 43.33 billion
Forecast Year [2032] USD 55.88 billion
CAGR (%) 4.32%

A comprehensive introduction that defines the demographic, clinical, regulatory, and technological forces reshaping genitourinary therapeutics and access

The genitourinary therapeutics landscape is in the midst of a dynamic evolution driven by demographic, clinical, and technological forces. Aging populations in advanced economies have elevated the prevalence of conditions such as benign prostatic hyperplasia and overactive bladder, while shifting care paradigms and patient expectations have intensified demand for medicines that balance efficacy with tolerability. Parallel advances in pharmacology and drug delivery are expanding therapeutic choices across oral, injectable, and topical modalities, offering clinicians more ways to personalize care.

At the same time, the sector is adapting to broader healthcare transformations. Digital health tools and telemedicine are changing how patients access consultations and prescriptions, with online pharmacies complementing traditional retail and hospital distribution channels. Payers and providers are increasingly focused on real-world evidence and value-based outcomes, prompting manufacturers to demonstrate comparative effectiveness and to invest in long-term safety data. Regulatory pathways are also evolving, with heightened scrutiny on post-marketing surveillance and on the quality of active pharmaceutical ingredients sourced from complex global supply chains.

Taken together, these trends underscore a critical inflection point for stakeholders across the ecosystem. Manufacturers, distributors, clinicians, and policymakers must align innovation with operational resilience, ensuring that new therapies reach appropriate patient populations while navigating pricing pressures, regulatory complexity, and shifting channels to care.

An in-depth exploration of the structural transformations in development, commercialization, and supply resilience that are redefining genitourinary care delivery

The genitourinary drug landscape is experiencing transformative shifts that extend beyond incremental product launches to structural changes in development, commercialization, and care delivery. Clinical innovation is broadening therapeutic frontiers through combination therapies and novel mechanisms of action, while formulation science is enabling alternative routes of administration that enhance adherence and tolerability. These scientific advances are converging with commercial shifts: digital-first patient engagement, the rise of online pharmacies, and greater emphasis on real-world evidence to substantiate value propositions.

Simultaneously, consolidation among manufacturers and strategic partnerships between pharma and technology firms are altering competitive dynamics. Companies are investing in data capabilities to support outcomes-based contracting and to generate post-approval insights that resonate with payers. On the supply side, there is an increasing focus on supply chain resilience, with manufacturers diversifying API sources and reassessing dependence on single geographies. Moreover, regulatory evolution-emphasizing pharmacovigilance and manufacturing quality-has prompted more proactive lifecycle management for mature assets.

These shifts are not isolated; they interact to create new windows of opportunity. Stakeholders who integrate innovations in therapeutic design with agile commercial models and robust evidence generation will be best positioned to capture clinical and market advantages, while those that lag in adapting distribution strategies or supply chain resilience risk erosion of market access and margin.

A focused analysis of how 2025 tariff changes influenced sourcing, procurement strategies, and commercial operations across the genitourinary pharmaceutical value chain

The implementation of United States tariff measures in 2025 has introduced a layered set of challenges and adaptive responses across the genitourinary drug value chain. Manufacturing inputs such as active pharmaceutical ingredients, excipients, and specialized packaging have become subject to heightened cost scrutiny, prompting companies to reassess sourcing strategies. In response, some manufacturers accelerated supplier diversification and explored regional sourcing alternatives to mitigate exposure to tariff-driven volatility. Others amplified strategic inventory management and forward contracting to smooth procurement costs across production cycles.

These adjustments have also influenced commercial operations and pricing strategies. Contract negotiations with distributors and institutional buyers have increasingly factored in input-cost uncertainty, underscoring the importance of transparent supply agreements and contingency clauses. Hospital pharmacies and larger healthcare systems have prioritized multi-source procurement to preserve formulary stability, while retail and online channels have monitored margin compression that could affect stocking decisions for higher-cost specialty agents.

Regulatory and compliance burdens have grown in parallel, as manufacturers document origin of materials with greater granularity to comply with trade rules and to support risk assessments. Ultimately, the tariff environment has reinforced the strategic imperative for operational flexibility: companies that combined cost-control measures with targeted investments in local manufacturing capability and supply chain traceability were better positioned to sustain product availability and collaborator confidence during a period of trade-related disruption.

Key segmentation insights that reveal how indication, therapeutic class, distribution channels, and formulation choices shape access, prescribing, and commercialization strategies

Segmentation nuances are central to understanding where clinical and commercial opportunities intersect within genitourinary therapeutics. Based on Indication the landscape spans Benign Prostatic Hyperplasia, Erectile Dysfunction, Interstitial Cystitis, Overactive Bladder, and Urinary Tract Infection, each presenting distinct patient journeys, diagnostic pathways, and endpoints that influence therapeutic choice and reimbursement conversations. Based on Therapeutic Class the field includes 5 Alpha Reductase Inhibitors, Alpha Blockers, Anticholinergics, Beta3 Agonists, Combination Therapies, and Pde5 Inhibitors, delineating both legacy standards of care and areas of active innovation.

Channel strategies differ considerably when viewed through the lens of Distribution Channel where Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies play complementary roles; the Hospital Pharmacies segment is further differentiated by Private Hospitals and Public Hospitals, and the Retail Pharmacies segment is further split into Chain Pharmacies and Independent Pharmacies, creating varied procurement practices and purchasing power dynamics. End User segmentation identifies Clinics, Homecare, and Hospitals as primary delivery contexts, with Clinics further classified into General Practice Clinics and Urology Clinics and Hospitals further segmented into Secondary Care Centers, Specialty Clinics, and Tertiary Care Centers, which shape prescribing patterns and access to specialist therapeutics.

Therapeutic delivery and commercial formulation also matter: Route Of Administration is categorized into Injectable, Oral, and Topical options while Formulation distinctions include Capsules, Injectable Solutions, Oral Solutions, and Tablets, each with implications for adherence, cold-chain logistics, and patient preference. Finally, Sales Model considerations separate Over The Counter from Prescription distribution, with the Over The Counter channel further subdivided into In-Store and Online modalities, influencing marketing approaches, margin structures, and regulatory oversight. Collectively, these segmentation dimensions reveal where clinical differentiation, reimbursement strategy, and distribution optimization must align for successful product adoption.

Critical regional insights highlighting how demographic, regulatory, and distribution differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific shape access and adoption

Regional dynamics exert a powerful influence on therapeutic priorities, regulatory environments, and distribution models within the genitourinary market. In the Americas demographic aging, a large primary care base, and a robust specialty care network drive sustained demand for chronic-condition management strategies, while reimbursement structures and formulary processes heighten the importance of clear value demonstration and outcomes data. Conversely, regional payer negotiations and public procurement mechanisms in Europe, Middle East & Africa produce diverse adoption curves, with some markets favoring centralized tenders and others emphasizing clinical guideline alignment.

In the Asia-Pacific region growth in healthcare infrastructure, rising middle-class demand for improved quality of care, and expanding telehealth platforms are creating new access pathways. Across all regions, distribution channel evolution-particularly the scaling of online pharmacies-interacts with local regulatory regimes to reshape patient access and adherence patterns. Differences in clinical practice, diagnostic rates, and treatment-seeking behavior also alter the relative importance of specific indications; for example, cultural attitudes toward sexual health can influence care-seeking for erectile dysfunction, while screening and diagnostic capacity affect identification of overactive bladder.

Taken together, these geographic distinctions require tailored market entry and commercialization tactics. Manufacturers and distributors must adapt evidence generation, pricing strategies, and channel engagement to local policy frameworks and patient behaviors in order to achieve sustainable access and therapeutic uptake across diverse regional contexts.

Strategic competitive analysis of how incumbent portfolios, specialty innovators, and partnerships drive differentiated positioning and commercialization success

Competitive dynamics in the genitourinary space are defined by a mix of established pharmaceutical leaders, specialty biopharmaceutical firms, and agile mid-sized companies that focus on niche indications or novel formulations. Large incumbent manufacturers maintain portfolio breadth across legacy therapeutic classes such as 5 Alpha Reductase Inhibitors and Alpha Blockers, leveraging commercial scale and established relationships with hospital and retail pharmacies. Specialty firms and newer entrants concentrate on differentiated mechanisms, combination therapies, and improved delivery systems that address tolerability or adherence issues, seeking to carve out value through physician engagement and targeted evidence generation.

Partnerships and licensing deals are common strategies to accelerate market access and to complement core capabilities, particularly where development expertise in formulation or regional commercialization networks is required. Companies are also investing in lifecycle management-reformulations, fixed-dose combinations, and extended-release technologies-to sustain competitiveness as therapeutic standards evolve. Additionally, firms that have developed robust digital engagement tools and outcomes-tracking platforms are gaining an advantage in payer discussions, enabling more persuasive value narratives anchored in real-world performance.

Across the competitive landscape, success increasingly depends on the integration of clinical differentiation with pragmatic commercialization plans. Organizations that align R&D investments with clear clinical unmet needs, while executing disciplined supply chain and channel strategies, are positioned to capture clinical adoption and to maintain durable commercial performance.

A pragmatic set of high-impact recommendations for pharmaceutical leaders to align R&D focus, supply chain resilience, and channel strategies to accelerate adoption

Industry leaders seeking to maximize clinical impact and commercial returns should adopt a set of actionable priorities that align innovation, access, and operational resilience. First, target development efforts toward indications with demonstrable unmet needs and invest in combination therapies or delivery technologies that improve adherence and tolerability, thereby strengthening value conversations with payers and clinicians. Second, enhance supply chain resilience by diversifying API and component sourcing, building regional manufacturing capacity where feasible, and instituting robust traceability protocols to reduce exposure to trade-related disruptions.

Third, tailor commercialization to channel realities: integrate online pharmacy strategies with traditional hospital and retail engagement, and develop channel-specific service offerings for chain versus independent pharmacies. Fourth, deploy real-world evidence generation programs and digital tools to support outcomes-based contracting and to substantiate long-term benefits; these initiatives should be closely linked to pharmacovigilance and post-marketing surveillance. Fifth, pursue strategic partnerships to extend geographic reach and to complement internal capabilities in formulation science, regulatory navigation, or localized commercial execution.

Taken together, these recommendations form a pragmatic roadmap: align R&D priorities with payer and clinician evidence needs, fortify supply chains, and execute nuanced channel strategies to ensure that clinical innovation translates into accessible, sustainable therapeutics for patients.

Transparent and reproducible research methodology combining primary expert engagement, secondary literature synthesis, and scenario-based operational analysis

This research synthesizes primary and secondary intelligence using a transparent, reproducible methodology that emphasizes source triangulation and expert validation. Primary inputs included structured interviews with clinicians, payers, distributors, and R&D leaders, combined with anonymized practitioner surveys designed to capture prescribing behavior and channel preferences. Secondary inputs comprised peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to contextualize clinical profiles, safety considerations, and formulation trends.

Analytical methods integrated qualitative synthesis with systematic evidence mapping to identify thematic shifts and competitive positioning. Supply chain and tariff impact assessments were constructed using input-cost sensitivity analysis and scenario testing to evaluate potential operational responses without presenting specific market sizing. Rigorous review cycles involved subject-matter experts in clinical urology, pharmacoeconomics, and supply chain management to validate assumptions and to refine conclusions. Data limitations and regional heterogeneities are explicitly noted throughout the report, and methodological appendices document interview protocols, inclusion criteria for secondary sources, and the logical steps used to derive strategic insights.

This approach ensures that findings are grounded in multiple perspectives and that recommendations reflect both clinical realities and commercial constraints, enabling stakeholders to apply the analysis with confidence across planning horizons.

A conclusion synthesizing how innovation, evidence generation, and supply chain robustness must be integrated to secure patient access and commercial sustainability

In conclusion, the genitourinary therapeutics space stands at a strategic crossroads where clinical innovation, distribution evolution, and operational resilience converge to determine future trajectories. Advances in therapeutic classes, combination regimens, and formulation technologies promise improved patient outcomes, but realizing that promise depends on aligning evidence generation with payer expectations, securing reliable supply chains, and adapting commercial models to an increasingly digital and channel-diverse environment. Stakeholders who invest in real-world data capabilities and who tailor market entry strategies to regional and channel-specific dynamics will be best positioned to transform clinical advances into durable patient access.

Concurrent challenges-such as trade-related cost pressures, regulatory scrutiny around manufacturing quality, and shifting patient expectations-require proactive mitigation through diversified sourcing, enhanced traceability, and stronger post-marketing surveillance. Ultimately, the institutions that integrate scientific differentiation with disciplined operational execution and nuanced channel engagement will deliver the greatest clinical value while maintaining commercial viability. This synthesis provides a strategic compass for executives, clinicians, and investors seeking to navigate a rapidly evolving market and to prioritize investments that deliver measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genitourinary Drugs Market, by Indication

  • 8.1. Benign Prostatic Hyperplasia
  • 8.2. Erectile Dysfunction
  • 8.3. Interstitial Cystitis
  • 8.4. Overactive Bladder
  • 8.5. Urinary Tract Infection

9. Genitourinary Drugs Market, by Therapeutic Class

  • 9.1. 5 Alpha Reductase Inhibitors
  • 9.2. Alpha Blockers
  • 9.3. Anticholinergics
  • 9.4. Beta3 Agonists
  • 9.5. Combination Therapies
  • 9.6. Pde5 Inhibitors

10. Genitourinary Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Genitourinary Drugs Market, by Formulation

  • 11.1. Capsules
  • 11.2. Injectable Solutions
  • 11.3. Oral Solutions
  • 11.4. Tablets

12. Genitourinary Drugs Market, by Sales Model

  • 12.1. Over The Counter
    • 12.1.1. In-Store
    • 12.1.2. Online
  • 12.2. Prescription

13. Genitourinary Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
    • 13.1.1. Private Hospitals
    • 13.1.2. Public Hospitals
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies
    • 13.3.1. Chain Pharmacies
    • 13.3.2. Independent Pharmacies

14. Genitourinary Drugs Market, by End User

  • 14.1. Clinics
    • 14.1.1. General Practice Clinics
    • 14.1.2. Urology Clinics
  • 14.2. Homecare
  • 14.3. Hospitals
    • 14.3.1. Secondary Care Centers
    • 14.3.2. Specialty Clinics
    • 14.3.3. Tertiary Care Centers

15. Genitourinary Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Genitourinary Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Genitourinary Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Genitourinary Drugs Market

19. China Genitourinary Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. Amgen Inc.
  • 20.8. Astellas Pharma Inc.
  • 20.9. AstraZeneca plc
  • 20.10. Aurobindo Pharma Limited
  • 20.11. Bayer AG
  • 20.12. Boehringer Ingelheim International GmbH
  • 20.13. Bristol-Myers Squibb Company
  • 20.14. Cipla Limited
  • 20.15. Dr. Reddy's Laboratories Limited
  • 20.16. Eli Lilly and Company
  • 20.17. Endo International plc
  • 20.18. F. Hoffmann-La Roche AG
  • 20.19. Ferring International Center S.A.
  • 20.20. GlaxoSmithKline plc
  • 20.21. Hikma Pharmaceuticals PLC
  • 20.22. Johnson & Johnson Services, Inc.
  • 20.23. Melinta Therapeutics Inc.
  • 20.24. Merck & Co., Inc.
  • 20.25. Novartis AG
  • 20.26. Pfizer Inc.
  • 20.27. Sanofi S.A.
  • 20.28. Takeda Pharmaceutical Company Limited
  • 20.29. Teva Pharmaceutical Industries Ltd.
  • 20.30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 251. GCC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 253. GCC GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GCC GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 288. G7 GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 289. G7 GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 290. G7 GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. G7 GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 292. G7 GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. G7 GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. NATO GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. NATO GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 301. NATO GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 302. NATO GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 303. NATO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. NATO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 305. NATO GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. NATO GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA GENITOURINARY DRUGS M